Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: A Chinese clinical study

Cytokine

Volumn 57, Issue 2, 2012, Pages 221-225

  Zhao, Sheng Jie ^a,b   Guo, Chun Ni ^a   Wang, Ming Qin ^a   Chen, Wei Jie ^c   Zhao, Yong Bo ^d  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Department of Geriatrics   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Mild cognitive impairment; Neurodegeneration; Peripheral inflammatory markers

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ALLELE; ARTICLE; CHINESE; CLINICAL STUDY; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; AMNESIA; APOLIPOPROTEIN E4; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHINA; COGNITION; DEMOGRAPHY; FEMALE; GENE FREQUENCY; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84855453747     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.006     Document Type: Article

References (48)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Clark C.M. Clinical manifestations and diagnostic evaluation of patients with Alzheimer's disease. Neurodegenerative dementias: clinical features and pathological mechanisms 2000, 95-114. McGraw Hill, New York.
3. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
4. Bouwman F.H., Schoonenboom N.S.M., Verwey N.A., et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009, 30:1895-1901.
5. Schoonenboom N.S., Pijnenburg Y.A., Mulder C., et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004, 62:1580-1584.
6. Fiala M., Veerhuis R. Biomarkers of inflammation and amyloid-b phagocytosis in patients at risk of Alzheimer disease. Exp Gerontol 2010, 45:57-63.
7. De Jager C.A., Budge M.M. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase 2005, 11:72-79.
8. McGeer Edith G., McGeer Patrick L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimer's Dis 2010, 19:355-361.
9. Zuliani G., Ranzini M., Guerra G., et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007, 41:686-693.
10. Sala Gessica, Galimberti Gloria, Canevari Carla, et al. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 2003, 24:909-914.
11. Eikelenboom P., Veerhuis R., Scheper W., et al. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Trans 2006, 111:1685-1695.
12. Schuitemaker A., Dik M.G., Veerhuis R., et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2009, 30:1885-1889.
13. Yang Y., Mufson E., Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003, 23:2557-2563.
14. Brian Giunta, Francisco Fernandez1, William V Nikolic, et a1. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflamm 2008;5:51.
15. Nilsson L.G., Adolfsson R., Bäckman L., et al. The influence of APOE status on episodic and semantic memory: data from a population-based study. Neuropsychology 2006, 20:645-657.
16. Wilson R.S., Schneider J.A., Barnes L.L., et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002, 59:1154-1160.
17. Deary I.J., Whiteman M.C., Pattie A., et al. Cognitive change, the APOE epsilon 4 allele. Nature 2002, 418:932. (Erratum in: Nature 2002 Oct 3. 419, 450).
18. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
19. Kester M.I., Verwey N.A., van Elk E.J., et al. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010, 31:357-367.
20. De Luigi A., Pizzimenti S., Quadri P., et al. Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis 2002, 11:308-314.
21. Lombardi V.R., Garcia M., Rey L., et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J Neuroimmunol 1999, 97:163-171.
22. Sando S.B., Melquist S., Cannon A., et al. APOEε4 lowers age at onset, is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol 2008, 8:9.
23. Kambch M.I. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol 1995, 67:195-215.
24. Chiang C.S., Stalder A., Samimi A., et al. Reactive gliosis as a consequence of interleukin-6 expression in the brain, Studies in transgenic mice. Dev Neurosci 1994, 16:212-221.
25. Sastre M., Dewachter I., Landreth G.E., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23:9796-9804.
26. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
27. Song M., Kellum J.A. Interleukin-6. Crit Care Med 2005, 33:463-465.
28. Medeiros R., Prediger R.D., Passos G.F., et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 2007, 27:5394-5404.
29. Wang Q., Wu J., Rowan M.J., Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005, 22:2827-2832.
30. Tarkowski E., Liljeroth A.M., Minthon L., et al. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003, 61:255-260.
31. Olson L., Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010, 45:41-46.
32. Laskowitz D.T., Goel S., Bennett E.R., et al. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997, 76:70-74.
33. Jofre-Monseny Laia, Minihane Anne-Marie, Rimbach Gerald Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008, 52:131-145.
34. Eiriksdottir G., Aspelund T., Bjarnadottir K., et al. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykja-vik study. Atherosclerosis 2006, 186:222-224.
35. Schuitemaker Alie, Dik Miranda G., Veerhuis Robert, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2009, 30(11):1885-1889.
36. Eiriksdottir G., Aspelund T., Bjarnadottir K., et al. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik study. Atherosclerosis 2006, 186:222-224.
37. Tziakas D.N., Chalikias G.K., Antonoglou C.O., et al. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol 2006, 48(12):2471-2481.
38. Drabe Natalie, Zu ènd Gregor, ènenfelder Ju èrg Gru, et al. Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur J Cardiothorac Surg 2001, 20:609-613.
39. Bermejoa Paloma, Marítn-Aragón Sagrario, Benedí Juana, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008, 117:198-202.
40. Rozzini L., Chilovi B.V., Conti M., et al. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry 2007, 22:1217-1222.
41. Zhao Shengjie, Guo Chunni, Wang Mingqin, et al. A clinical memory battery for screening for amnestic mild cognitive impairment in an elderly Chinese population. J Clin Neurosci 2011, 18:774-779.
42. Walter Swardfager, Krista Lanctôt, Lana Rothenburg, et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010; Article in press. doi:10.1016/j.biopsych. 2010.06.012.
43. Akiyama Haruhiko, Barger Steven, Barnum Scott, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
44. Teunissen C.E., van Boxtel M.P., Bosma H., et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003, 134(1-2):142-150.
45. Pollmacher T., Haack M., Schuld A., Reichenberg A., Yirmiya R. Low levels of circulating inflammatory cytokines-do they affect human brain functions?. Brain Behav Immun 2002, 16:525-532.
46. Quintanilla R.A., Orellana D.I., Gonzalez C., Maccioni R.B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295:245-257.
47. Yaffe K., Lindquist K., Pennix B.W., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
48. Beloosesky Y., Salman H., Bergman M., et al. Cytokine levels and phagocytic activity in patients with Alzheimer's disease. Gerontology 2002, 48:128-132.